In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial ScienceDirect Modulatory effects of BPC 157 on vasomotor tone and the activation of Src Caveolin 1 endothelial nitric oxide synthase pathway Scientific Reports Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review Interview with Dr. Tyna Moore, ND, DC What Women Need to Know About GLP 1 Microdosing, Peptides, Gut Health, and Hormonal Optimization THAIS ALIABADI MD